Erik Ostrowski - 30 Jan 2026 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role
SVP, CFO, CBO & Treasurer
Signature
/s/ Carolyn M. Rucci, attorney-in-fact for Erik Ostrowski
Issuer symbol
AKBA
Transactions as of
30 Jan 2026
Net transactions value
$0
Form type
4
Filing time
03 Feb 2026, 16:36:36 UTC
Previous filing
01 Jul 2025
Next filing
04 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ostrowski Erik SVP, CFO, CBO & Treasurer C/O AKEBIA THERAPEUTICS, INC, 245 FIRST ST., CAMBRIDGE /s/ Carolyn M. Rucci, attorney-in-fact for Erik Ostrowski 03 Feb 2026 0001762507

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKBA Common Stock Award $0 +204,000 +41% $0.000000 707,586 30 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKBA Stock Option (Right to buy) Award $0 +320,000 $0.000000 320,000 30 Jan 2026 Common Stock 320,000 $1.41 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
F2 The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.